_id
6915f343bc934aba376b21bf
Ticker
SABSW
Name
SAB Biotherapeutics Inc
Exchange
NASDAQ
Address
777 W 41st St., Miami Beach, FL, United States, 33140
Country
USA
Sector
Industry
Currency
USD
Website
https://www.sabbiotherapeutics.com
Description
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Last Close
0.0271
Volume
17362
Current Price
0.0295
Change
-0.0002
Last Updated
2026-01-06T10:40:30.895Z
Image
-
Ipo Date
2021-02-09T00:00:00.000Z
Market Cap
-
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
765469
Gross Profit
-765469
Operating Expenses
11913500
Operating Income
-12678969
Interest Expense
43292
Pretax Income
45445469
Net Income
5337665
Eps
0.06855177646485223
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
-
EBITDA
46254230
Operating Margin
-
Total Other Income Expense Net
58124438
Cash
29424708
Short Term Investments
81455925
Receivables
559954
Inventories
-
Total Current Assets
113276747
Property Plant Equipment
19438961
Total Assets
183448368
Payables
2954985
Short Term Debt
988319
Long Term Debt
-
Total Liabilities
18374019
Equity
165074349
Bs_currency_symbol
USD
Depreciation
765469
Change In Working Capital
1623693
Cash From Operations
-13050023
Capital Expenditures
3
Cash From Investing
-129868914
Cash From Financing
168688966
Net Change In Cash
25732491
Cf_currency_symbol
USD
PE
0.1062
PB
0.01391473764648922
ROE
3.233491473590485
ROA
2.9096279559161844
FCF
-13050026
Fcf Percent
-
Piotroski FScore
2
Health Score
62
Deep Value Investing Score
7.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
5.8
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
4
Net Net Investing Score
2
Quality Investing Score
5
Value Investing Score
8
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
765469
Quarters > 0 > income Statement > gross Profit
-765469
Quarters > 0 > income Statement > operating Expenses
11913500
Quarters > 0 > income Statement > operating Income
-12678969
Quarters > 0 > income Statement > interest Expense
43292
Quarters > 0 > income Statement > pretax Income
45445469
Quarters > 0 > income Statement > net Income
5337665
Quarters > 0 > income Statement > eps
0.06855177646485223
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
77863263
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
46254230
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
58124438
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
29424708
Quarters > 0 > balance Sheet > short Term Investments
81455925
Quarters > 0 > balance Sheet > receivables
559954
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
113276747
Quarters > 0 > balance Sheet > property Plant Equipment
19438961
Quarters > 0 > balance Sheet > total Assets
183448368
Quarters > 0 > balance Sheet > payables
2954985
Quarters > 0 > balance Sheet > short Term Debt
988319
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
18374019
Quarters > 0 > balance Sheet > equity
165074349
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
5337665
Quarters > 0 > cash Flow > depreciation
765469
Quarters > 0 > cash Flow > change In Working Capital
1623693
Quarters > 0 > cash Flow > cash From Operations
-13050023
Quarters > 0 > cash Flow > capital Expenditures
3
Quarters > 0 > cash Flow > cash From Investing
-129868914
Quarters > 0 > cash Flow > cash From Financing
168688966
Quarters > 0 > cash Flow > net Change In Cash
25732491
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
0.06855177646485223
Quarters > 0 > ratios > PB
0.01391473764648922
Quarters > 0 > ratios > ROE
3.233491473590485
Quarters > 0 > ratios > ROA
2.9096279559161844
Quarters > 0 > ratios > FCF
-13050026
Quarters > 0 > ratios > Piotroski FScore
2
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
62
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
822000
Quarters > 1 > income Statement > gross Profit
-822000
Quarters > 1 > income Statement > operating Expenses
8910061
Quarters > 1 > income Statement > operating Income
-9732061
Quarters > 1 > income Statement > interest Expense
64345
Quarters > 1 > income Statement > pretax Income
-10114270
Quarters > 1 > income Statement > net Income
-10114270
Quarters > 1 > income Statement > eps
-1.0882031022966454
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
9294469
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-9227925
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-382209
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
3692217
Quarters > 1 > balance Sheet > short Term Investments
2021335
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
9308121
Quarters > 1 > balance Sheet > property Plant Equipment
20403881
Quarters > 1 > balance Sheet > total Assets
30129488
Quarters > 1 > balance Sheet > payables
2622357
Quarters > 1 > balance Sheet > short Term Debt
963220
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
18113273
Quarters > 1 > balance Sheet > equity
12016215
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-10114270
Quarters > 1 > cash Flow > depreciation
774517
Quarters > 1 > cash Flow > change In Working Capital
942800
Quarters > 1 > cash Flow > cash From Operations
-7151544
Quarters > 1 > cash Flow > capital Expenditures
4
Quarters > 1 > cash Flow > cash From Investing
5197837
Quarters > 1 > cash Flow > cash From Financing
-173844
Quarters > 1 > cash Flow > net Change In Cash
-1948150
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-1.0882031022966454
Quarters > 1 > ratios > PB
0.022818070041190176
Quarters > 1 > ratios > ROE
-84.17184612625523
Quarters > 1 > ratios > ROA
-33.569339113894
Quarters > 1 > ratios > FCF
-7151548
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
32
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
778301
Quarters > 2 > income Statement > gross Profit
-778301
Quarters > 2 > income Statement > operating Expenses
9993801
Quarters > 2 > income Statement > operating Income
-10772102
Quarters > 2 > income Statement > interest Expense
69565
Quarters > 2 > income Statement > pretax Income
-5196773
Quarters > 2 > income Statement > net Income
-5196773
Quarters > 2 > income Statement > eps
-0.5592738915195867
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
9292000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-4348904
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
5575329
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
5640367
Quarters > 2 > balance Sheet > short Term Investments
7209999
Quarters > 2 > balance Sheet > receivables
21386
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
16296709
Quarters > 2 > balance Sheet > property Plant Equipment
21373559
Quarters > 2 > balance Sheet > total Assets
38120062
Quarters > 2 > balance Sheet > payables
2520390
Quarters > 2 > balance Sheet > short Term Debt
1077247
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
16712563
Quarters > 2 > balance Sheet > equity
21407499
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-5196773
Quarters > 2 > cash Flow > depreciation
778301
Quarters > 2 > cash Flow > change In Working Capital
1064523
Quarters > 2 > cash Flow > cash From Operations
-7797217
Quarters > 2 > cash Flow > capital Expenditures
3
Quarters > 2 > cash Flow > cash From Investing
4671103
Quarters > 2 > cash Flow > cash From Financing
-173985
Quarters > 2 > cash Flow > net Change In Cash
-3257599
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.5592738915195867
Quarters > 2 > ratios > PB
0.012804578433006114
Quarters > 2 > ratios > ROE
-24.275479354220685
Quarters > 2 > ratios > ROA
-13.632645718152295
Quarters > 2 > ratios > FCF
-7797220
Quarters > 2 > ratios > Piotroski FScore
0
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
37
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
114698
Quarters > 3 > income Statement > cost Of Revenue
785713
Quarters > 3 > income Statement > gross Profit
-671015
Quarters > 3 > income Statement > operating Expenses
9337825
Quarters > 3 > income Statement > operating Income
-10008840
Quarters > 3 > income Statement > interest Expense
70876
Quarters > 3 > income Statement > pretax Income
-11394699
Quarters > 3 > income Statement > net Income
-11394699
Quarters > 3 > income Statement > eps
-1.2302633340531204
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
9262000
Quarters > 3 > income Statement > income Tax Expense
13375362
Quarters > 3 > income Statement > EBITDA
-10538107
Quarters > 3 > income Statement > operating Margin
-8726.255034961378
Quarters > 3 > income Statement > total Other Income Expense Net
-1385859
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
8897966
Quarters > 3 > balance Sheet > short Term Investments
11862746
Quarters > 3 > balance Sheet > receivables
54955
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
23792229
Quarters > 3 > balance Sheet > property Plant Equipment
19921138
Quarters > 3 > balance Sheet > total Assets
44195469
Quarters > 3 > balance Sheet > payables
1694722
Quarters > 3 > balance Sheet > short Term Debt
811842
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
18225893
Quarters > 3 > balance Sheet > equity
25969576
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-11394699
Quarters > 3 > cash Flow > depreciation
785713
Quarters > 3 > cash Flow > change In Working Capital
-1884347
Quarters > 3 > cash Flow > cash From Operations
-9271083
Quarters > 3 > cash Flow > capital Expenditures
55377
Quarters > 3 > cash Flow > cash From Investing
9330766
Quarters > 3 > cash Flow > cash From Financing
-44144
Quarters > 3 > cash Flow > net Change In Cash
-273209
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-1.2302633340531204
Quarters > 3 > ratios > PB
0.010521119020195015
Quarters > 3 > ratios > ROE
-43.87710835171125
Quarters > 3 > ratios > ROA
-25.78250498936893
Quarters > 3 > ratios > FCF
-9326460
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-81.31318767546078
Quarters > 3 > health Score
30
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
1322410
Annuals > 0 > income Statement > cost Of Revenue
4792595
Annuals > 0 > income Statement > gross Profit
-3470185
Annuals > 0 > income Statement > operating Expenses
39440335
Annuals > 0 > income Statement > operating Income
-42910520
Annuals > 0 > income Statement > interest Expense
318401
Annuals > 0 > income Statement > pretax Income
-34105309
Annuals > 0 > income Statement > net Income
-34105309
Annuals > 0 > income Statement > eps
-3.682283416108832
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
9262000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-28994318
Annuals > 0 > income Statement > operating Margin
-3244.872618930589
Annuals > 0 > income Statement > total Other Income Expense Net
8805211
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
8897966
Annuals > 0 > balance Sheet > short Term Investments
11862746
Annuals > 0 > balance Sheet > receivables
54955
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
23792229
Annuals > 0 > balance Sheet > property Plant Equipment
19921138
Annuals > 0 > balance Sheet > total Assets
44195469
Annuals > 0 > balance Sheet > payables
1694722
Annuals > 0 > balance Sheet > short Term Debt
811842
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
18225893
Annuals > 0 > balance Sheet > equity
25969576
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-34105309
Annuals > 0 > cash Flow > depreciation
4792595
Annuals > 0 > cash Flow > change In Working Capital
-2298989
Annuals > 0 > cash Flow > cash From Operations
-34292009
Annuals > 0 > cash Flow > capital Expenditures
337262
Annuals > 0 > cash Flow > cash From Investing
-11962267
Annuals > 0 > cash Flow > cash From Financing
-1172626
Annuals > 0 > cash Flow > net Change In Cash
-47668100
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-3.682283416108832
Annuals > 0 > ratios > PB
0.011056091173764254
Annuals > 0 > ratios > ROE
-131.32793927786884
Annuals > 0 > ratios > ROA
-77.16924329957897
Annuals > 0 > ratios > FCF
-34629271
Annuals > 0 > ratios > Piotroski FScore
1
Annuals > 0 > ratios > fcf Percent
-26.18648603685695
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
2239000
Annuals > 1 > income Statement > cost Of Revenue
3745000
Annuals > 1 > income Statement > gross Profit
-1506000
Annuals > 1 > income Statement > operating Expenses
36569000
Annuals > 1 > income Statement > operating Income
-38075000
Annuals > 1 > income Statement > interest Expense
315284
Annuals > 1 > income Statement > pretax Income
-42194000
Annuals > 1 > income Statement > net Income
-42194000
Annuals > 1 > income Statement > eps
-7.642456076797681
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
5521000
Annuals > 1 > income Statement > income Tax Expense
-2
Annuals > 1 > income Statement > EBITDA
-38133000
Annuals > 1 > income Statement > operating Margin
-1700.5359535506923
Annuals > 1 > income Statement > total Other Income Expense Net
-4118000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
56566066
Annuals > 1 > balance Sheet > short Term Investments
0
Annuals > 1 > balance Sheet > receivables
0
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
58906863
Annuals > 1 > balance Sheet > property Plant Equipment
24684160
Annuals > 1 > balance Sheet > total Assets
83941253
Annuals > 1 > balance Sheet > payables
945927
Annuals > 1 > balance Sheet > short Term Debt
1852799
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
26641812
Annuals > 1 > balance Sheet > equity
57299441
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-42193786
Annuals > 1 > cash Flow > depreciation
3745282
Annuals > 1 > cash Flow > change In Working Capital
2326219
Annuals > 1 > cash Flow > cash From Operations
-25119405
Annuals > 1 > cash Flow > capital Expenditures
197154
Annuals > 1 > cash Flow > cash From Investing
-152704
Annuals > 1 > cash Flow > cash From Financing
66773137
Annuals > 1 > cash Flow > net Change In Cash
41519172
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-7.642456076797681
Annuals > 1 > ratios > PB
0.0029869575865495786
Annuals > 1 > ratios > ROE
-73.63771664020248
Annuals > 1 > ratios > ROA
-50.26610694029073
Annuals > 1 > ratios > FCF
-25316559
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-11.307083072800358
Annuals > 1 > health Score
33
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
23904000
Annuals > 2 > income Statement > cost Of Revenue
3292000
Annuals > 2 > income Statement > gross Profit
20612000
Annuals > 2 > income Statement > operating Expenses
49529920
Annuals > 2 > income Statement > operating Income
-28918000
Annuals > 2 > income Statement > interest Expense
301584
Annuals > 2 > income Statement > pretax Income
-18715371
Annuals > 2 > income Statement > net Income
-18741000
Annuals > 2 > income Statement > eps
-4.306295955882353
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
4352000
Annuals > 2 > income Statement > income Tax Expense
25629
Annuals > 2 > income Statement > EBITDA
-15122000
Annuals > 2 > income Statement > operating Margin
-120.97556894243641
Annuals > 2 > income Statement > total Other Income Expense Net
10202629
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
15046894
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
5556577
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
22097453
Annuals > 2 > balance Sheet > property Plant Equipment
28339780
Annuals > 2 > balance Sheet > total Assets
50904927
Annuals > 2 > balance Sheet > payables
3679116
Annuals > 2 > balance Sheet > short Term Debt
1396247
Annuals > 2 > balance Sheet > long Term Debt
541644
Annuals > 2 > balance Sheet > total Liabilities
19846785
Annuals > 2 > balance Sheet > equity
31058142
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-18740804
Annuals > 2 > cash Flow > depreciation
3291878
Annuals > 2 > cash Flow > change In Working Capital
-237575
Annuals > 2 > cash Flow > cash From Operations
-23459511
Annuals > 2 > cash Flow > capital Expenditures
2166414
Annuals > 2 > cash Flow > cash From Investing
-2090024
Annuals > 2 > cash Flow > cash From Financing
1051411
Annuals > 2 > cash Flow > net Change In Cash
-24498124
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-4.306295955882353
Annuals > 2 > ratios > PB
0.004343852893711414
Annuals > 2 > ratios > ROE
-60.34166499721716
Annuals > 2 > ratios > ROA
-36.815689766139926
Annuals > 2 > ratios > FCF
-25625925
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-1.072035015060241
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
60876000
Annuals > 3 > income Statement > cost Of Revenue
1654000
Annuals > 3 > income Statement > gross Profit
59222000
Annuals > 3 > income Statement > operating Expenses
72615684
Annuals > 3 > income Statement > operating Income
-13393000
Annuals > 3 > income Statement > interest Expense
294459
Annuals > 3 > income Statement > pretax Income
-17145000
Annuals > 3 > income Statement > net Income
-17145000
Annuals > 3 > income Statement > eps
-6.271031455742502
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
2734000
Annuals > 3 > income Statement > income Tax Expense
299947
Annuals > 3 > income Statement > EBITDA
-15196000
Annuals > 3 > income Statement > operating Margin
-22.00045995137657
Annuals > 3 > income Statement > total Other Income Expense Net
-3751000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
33206712
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
8010708
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
50191950
Annuals > 3 > balance Sheet > property Plant Equipment
30948981
Annuals > 3 > balance Sheet > total Assets
81140931
Annuals > 3 > balance Sheet > payables
4458525
Annuals > 3 > balance Sheet > short Term Debt
3100187
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
42591018
Annuals > 3 > balance Sheet > equity
38549913
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-17144531
Annuals > 3 > cash Flow > depreciation
1653597
Annuals > 3 > cash Flow > change In Working Capital
11683141
Annuals > 3 > cash Flow > cash From Operations
1986873
Annuals > 3 > cash Flow > capital Expenditures
10943653
Annuals > 3 > cash Flow > cash From Investing
-10943657
Annuals > 3 > cash Flow > cash From Financing
35891419
Annuals > 3 > cash Flow > net Change In Cash
26934635
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-6.271031455742502
Annuals > 3 > ratios > PB
0.0021985523028288027
Annuals > 3 > ratios > ROE
-44.47480854236947
Annuals > 3 > ratios > ROA
-21.129902983242825
Annuals > 3 > ratios > FCF
-8956780
Annuals > 3 > ratios > Piotroski FScore
2
Annuals > 3 > ratios > fcf Percent
-0.14713154609369866
Annuals > 3 > health Score
25
Valuation > metrics > PE
0.1062
Valuation > metrics > PB
0.01391473764648922
Valuation > final Score
90
Valuation > verdict
98.8% Undervalued
Profitability > metrics > ROE
3.233491473590485
Profitability > metrics > ROA
4.71205710029791
Profitability > final Score
36
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.1113075357334894
Risk > metrics > Interest Coverage
-292.8709461332348
Risk > final Score
-1111
Risk > verdict
High
Liquidity > metrics > Current Ratio
28.72635409291295
Liquidity > metrics > Quick Ratio
28.72635409291295
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
70
Prev Valuations > 1
70
Prev Valuations > 2
70
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-575
Prev Risks > 1
-571
Prev Risks > 2
-517
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:31:17.100Z
Earnings History > 0 > period
2021-06-30
Earnings History > 0 > report Date
2021-09-30
Earnings History > 0 > date
2021-06-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
USD
Earnings History > 0 > eps Actual
-0.12
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
-0.12
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2021-03-31
Earnings History > 1 > report Date
2021-06-30
Earnings History > 1 > date
2021-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
USD
Earnings History > 1 > eps Actual
-0.0217
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-0.0217
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-12-31
Earnings History > 2 > report Date
2021-03-31
Earnings History > 2 > date
2020-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
USD
Earnings History > 2 > eps Actual
-0.0217
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-0.0217
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-09-30
Earnings History > 3 > report Date
2020-12-31
Earnings History > 3 > date
2020-09-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
0.1575
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
0.1575
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-06-30
Earnings History > 4 > report Date
2020-09-30
Earnings History > 4 > date
2020-06-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
0.1657
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
0.1657
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2020-03-31
Earnings History > 5 > report Date
2020-06-30
Earnings History > 5 > date
2020-03-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
0.0151
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
0.0151
Earnings History > 5 > surprise Percent
-
Earnings History > 6 > period
2019-12-31
Earnings History > 6 > report Date
2020-03-31
Earnings History > 6 > date
2019-12-31
Earnings History > 6 > before After Market
-
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
0.0151
Earnings History > 6 > eps Estimate
0
Earnings History > 6 > eps Difference
0.0151
Earnings History > 6 > surprise Percent
-
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAug Setups: Is Artius II Acquisition Inc Equity Right benefiting from interest rate changes - 2025 Big Picture & Low Drawdown Trading Techniques baoquankhu1.vn
Read more →Why HPS stock is a must watch ticker - 2025 Support & Resistance & Accurate Buy Signal Notifications bollywoodhelpline.com
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of SAB Biotherapeutics Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2021-06-30
EPS Actual
-0.12
EPS Estimate
0
EPS Difference
-0.12
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.